0.07Open0.07Pre Close0 Volume269 Open Interest50.00Strike Price0.00Turnover694.49%IV1520.39%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type0.0618Delta0.0309Gamma44.14Leverage Ratio-0.0182Theta0.0000Rho2.73Eff Leverage0.0007Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet